** Shares of ResMed , Inspire Medical fall premarket after Eli Lilly's weight-loss drug succeeds in trials testing it in sleep apnea patients
** ResMed shares down 6.6% to 172.60, Inspire Medical stock falls 7.7% to $204.50
** Lilly's weight-loss drug helped cut frequency of irregular breathing in patients with obstructive sleep apnea by as much as 63% on average across two late-stage trials
** LLY shares up 1.2% to $755.72
** ResMed and Inspire Medical make medical devices used to treat sleep apnea, a potentially serious sleep disorder in which breathing repeatedly stops and starts
** As of last close, RMD shares up 7.5% YTD, INSP up ~9%
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com))
Comments